Edison Pharmaceuticals Licenses Drug from Centocor for Rare Diseases
Broadens pipeline for orphan and neglected diseases
MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has licensed CNTO-530, a clinical-stage compound discovered and developed by Centocor R&D, Inc. for clinical evaluation in rare mitochondrial and other neglected diseases. The terms of the transaction have not been disclosed.
About Edison Pharmaceuticals
Edison Pharmaceuticals is dedicated to developing treatments for children with rare energy-related diseases. The Company's initial focus is on inherited diseases of the mitochondria. Edison is leveraging insights from those studies to pursue other diseases that share common mechanisms.
SOURCE Edison Pharmaceuticals, Inc.
More by this Source
Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Mar 28, 2013, 08:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.